|1.||Miller, John H: 7 articles (09/2015 - 08/2011)|
|2.||Northcote, Peter T: 6 articles (09/2015 - 08/2011)|
|3.||Kanakkanthara, Arun: 5 articles (09/2015 - 08/2011)|
|4.||Teesdale-Spittle, Paul H: 2 articles (09/2015 - 01/2014)|
|5.||Hanna, Reem: 2 articles (01/2014 - 11/2013)|
|6.||Bellows, David S: 2 articles (01/2014 - 11/2013)|
|7.||Atkinson, Paul H: 2 articles (01/2014 - 11/2013)|
|8.||Rawson, Pisana: 2 articles (11/2012 - 08/2011)|
|9.||Hamel, Ernest: 2 articles (08/2011 - 07/2002)|
|10.||O'Brate, Aurora: 2 articles (08/2011 - 07/2002)|
05/01/2007 - "However, despite demonstrating promise in cell-based and pharmacokinetic studies, laulimalide exhibited only minimal tumor growth inhibition in vivo and was accompanied by severe toxicity and mortality. "
01/01/2014 - "Thus, we conclude that yeast is an appropriate model to screen for small molecule drugs that may be efficacious in cancer therapy in humans through the newly characterised laulimalide-peloruside binding site. "
05/01/2007 - "Our in vitro results with synthetic material confirmed the previous reports that laulimalide is a mitotic blocker that can inhibit the growth of a variety of both non-MDR and MDR human cancer cell lines. "
11/01/2002 - "In the past few years, the microtubule stabilizing agent (-)-laulimalide has attracted considerable attention, as it could constitute a potential treatment for cancer. "
08/01/2015 - "The new contacts between the drug and the microtubule structure not only improve our understanding of laulimalide binding but also will be essential for efficient derivatization and optimization of this prospective cancer chemotherapy agent. "
05/02/2005 - "Novel, simplified analogues of the microtubule-stabilizing anticancer agent laulimalide, including the first derivatives with unnatural side chains, were designed by molecular modelling, synthesized by a late-stage diversification strategy, and evaluated in vitro for growth inhibition of human ovarian carcinoma cell lines (A2780, A2780/AD10)."
08/01/2011 - "We developed peloruside A- and laulimalide-resistant cell lines by selecting 1A9 human ovarian carcinoma cells that were able to grow in the presence of one of these agents. "
08/01/2011 - "Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes."
11/01/2012 - "Acquired resistance to peloruside A and laulimalide is associated with downregulation of vimentin in human ovarian carcinoma cells."
11/01/2012 - "Acquired β-tubulin alterations in human ovarian carcinoma 1A9 cells were previously shown to confer resistance to the microtubule stabilizing agents peloruside A (PLA) and laulimalide (LAU). "
|3.||Ovarian Neoplasms (Ovarian Cancer)
02/01/2012 - "A human ovarian cancer cell line, 1A9-L4 (L4), previously selected in high concentrations of laulimalide, has both a single point mutation in βI-tubulin and overexpression of βII- and βIII-tubulin. "
01/01/2014 - "We recently showed that peloruside A (PLA) and laulimalide (LAU)-resistant cancer cell lines, 1A9-R1 (R1) and 1A9-L4 (L4), generated through multi-step selection of human 1A9 ovarian cancer cells with high concentrations of either PLA (for R1) or LAU (for L4) have single distinct mutations in their βI-tubulin gene. "
|1.||Drug Therapy (Chemotherapy)